Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML.

Autor:	Menghrajani K; Leukemia Service and., Gomez-Arteaga A; Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY., Madero-Marroquin R; Department of Medicine, Icahn School of Medicine, Mount Sinai St Luke's and Mount Sinai West, New York, NY., Zhang MJ; Center for International Blood and Marrow Transplant Research (CIBMTR), Department of Medicine and.; Division of Biostatistics, Institute for Health and Equity, Medical College of Wisconsin, Milwaukee, WI., Bo-Subait K; Center for International Blood and Marrow Transplant Research (CIBMTR), Department of Medicine and., Sanchez J; Center for International Blood and Marrow Transplant Research (CIBMTR), Department of Medicine and., Wang HL; Center for International Blood and Marrow Transplant Research (CIBMTR), Department of Medicine and., Aljurf M; Department of Oncology, King Faisal Specialist Hospital Center and Research, Riyadh, Saudi Arabia., Assal A; Department of Medicine, Bone Marrow Transplant and Cell Therapy Program, Columbia University Irving Medical Center, New York, NY., Bacher VU; Department of Hematology, Inselspital, Bern University Hospital, University of Bern, Switzerland., Badawy SM; Division of Hematology, Oncology and Stem Cell Transplant, Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, IL.; Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, IL., Bejanyan N; Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL., Bhatt VR; The Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE., Bredeson C; The Ottawa Hospital Blood and Marrow Transplant Program, Ottawa ON, Canada.; Ottawa Hospital Research Institute, Ottawa, ON, Canada., Byrne M; Division of Hematology and Oncology, Vanderbilt University Medical Center, Nashville, TN., Castillo P; Division of Hematology & Oncology, Department of Pediatrics in the College of Medicine, UF Health Shands Children's Hospital, Gainesville, FL., Cerny J; Division of Hematology/Oncology, Department of Medicine, University of Massachusetts Medical Center, Worcester, MA., Chhabra S; Center for International Blood and Marrow Transplant Research (CIBMTR), Department of Medicine and.; Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI., Ciurea SO; Division of Cancer Medicine, Department of Stem Cell Transplantation, The University of Texas MD Anderson Cancer Center, Houston, TX., DeFilipp Z; Blood and Marrow Transplant Program, Massachusetts General Hospital, Boston, MA., Farhadfar N; Division of Hematology/Oncology, University of Florida College of Medicine, Gainesville, FL., Gadalla S; Division of Cancer Epidemiology and Genetics, National Cancer Institute (NCI) Clinical Genetics Branch, National Institutes of Health (NIH), Rockville, MD., Gale RP; Haematology Research Centre, Department of Immunology and Inflammation, Imperial College London, London, United Kingdom., Ganguly S; Division of Hematological Malignancy and Cellular Therapeutics, University of Kansas Health System, Kansas City, KS., Gowda L; Section of Hematology, Department of Medicine, Yale University School of Medicine, Yale Comprehensive Cancer Center, Yale New Haven Hospital, New Haven, CT., Grunwald MR; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC., Hashmi S; Department of Internal Medicine, Mayo Clinic, Rochester, MN.; Oncology Center, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia., Hildebrandt G; Markey Cancer Center, University of Kentucky, Lexington, KY., Kanakry CG; Experimental Transplantation and Immunology Branch, Center for Cancer Research, NCI, NIH, Bethesda, MD., Kansagra A; UT Southwestern Medical Center, Blood and Marrow Transplant Program, Dallas, TX., Khimani F; H Lee Moffitt Cancer Center and Research Institute, Tampa, FL., Krem M; Markey Cancer Center, University of Kentucky College of Medicine, Lexington, KY., Lazarus H; Department of Medicine, University Hospitals Case Medical Center and Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH., Liu H; Section of Hematology/Oncology, University of Chicago Medicine, Chicago, IL., Martino R; Division of Clinical Hematology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain., Michelis FV; Allogeneic Blood and Marrow Transplant Program, Princess Margaret Cancer Centre, Toronto, ON, Canada., Nathan S; Section of Bone Marrow Transplant and Cell Therapy, Rush University Medical Center, Chicago, IL., Nishihori T; The Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE., Olsson R; Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.; Centre for Clinical Research Sormland, Uppsala University, Uppsala, Sweden., Reshef R; Blood and Marrow Transplantation Program and.; Columbia Center for Translational Immunology, Columbia University Medical Center, New York, NY., Rizzieri D; Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC., Rowe JM; Department of Hematology, Shaare Zedek Medical Center, Jerusalem, Israel., Savani BN; Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN., Seo S; Department of Hematology and Oncology, Dokkyo Medical University, Tochigi, Japan., Sharma A; Department of Bone Marrow Transplantation and Cellular Therapy, St Jude Children's Research Hospital, Memphis, TN., Solh M; The Blood and Marrow Transplant Group of Georgia, Northside Hospital, Atlanta, GA., Ustun C; Hematology, Oncology, and Cell Therapy, Rush University Medical Center, Chicago, IL., Verdonck LF; Department of Hematology and Oncology, Isala Clinic, Zwolle, The Netherlands., Hourigan C; National Heart Lung, and Blood Institute, NIH, Bethesda, MD., Sandmaier B; Division of Medical Oncology, University of Washington, Seattle, WA.; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA., Litzow M; Division of Hematology and Transplant Center, Mayo Clinic Rochester, Rochester, MN., Kebriaei P; Department of Stem Cell Transplantation, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX., Weisdorf D; Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN; and., Zhang Y; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY., Tallman MS; Leukemia Service and.; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY., Saber W; Center for International Blood and Marrow Transplant Research (CIBMTR), Department of Medicine and.
Jazyk:	angličtina
Zdroj:	Blood advances [Blood Adv] 2022 Jan 08; Vol. 6 (3), pp. 828-847.
DOI:	10.1182/bloodadvances.2021004881
Abstrakt:	Little is known about whether risk classification at diagnosis predicts post-hematopoietic cell transplantation (HCT) outcomes in patients with acute myeloid leukemia (AML). We evaluated 8709 patients with AML from the CIBMTR database, and after selection and manual curation of the cytogenetics data, 3779 patients in first complete remission were included in the final analysis: 2384 with intermediate-risk, 969 with adverse-risk, and 426 with KMT2A-rearranged disease. An adjusted multivariable analysis detected an increased risk of relapse for patients with KMT2A-rearranged or adverse-risk AML as compared to those with intermediate-risk disease (hazards ratio [HR], 1.27; P = .01; HR, 1.71; P < .001, respectively). Leukemia-free survival was similar for patients with KMT2A rearrangement or adverse risk (HR, 1.26; P = .002, and HR, 1.47; P < .001), as was overall survival (HR, 1.32; P < .001, and HR, 1.45; P < .001). No differences in outcome were detected when patients were stratified by KMT2A fusion partner. This study is the largest conducted to date on post-HCT outcomes in AML, with manually curated cytogenetics used for risk stratification. Our work demonstrates that risk classification at diagnosis remains predictive of post-HCT outcomes in AML. It also highlights the critical need to develop novel treatment strategies for patients with KMT2A-rearranged and adverse-risk disease. (© 2022 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu